Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

The class B glucagon-like peptide-1 (GLP-1) G protein-coupled receptor is a major target for
the treatment of type 2 diabetes and obesity. Endogenous and mimetic GLP-1 peptides …

Peptide drugs targeting class B1 G-protein-coupled receptors (GPCRs) can treat multiple
diseases; however, there remains substantial interest in the development of orally delivered …

Class B G-protein-coupled receptors are major targets for the treatment of chronic diseases,
including diabetes and obesity. Structures of active receptors reveal peptide agonists …

The glucagon-like peptide 1 receptor (GLP1R) is a major drug target with several agonists
being prescribed in individuals with type 2 diabetes and obesity,. The impact of genetic …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …

Peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) have revolutionized
diabetes therapy, but their use has been limited because they require injection. Herein, we …

G protein-coupled receptors (GPCRs) are allosteric proteins, because their signal
transduction relies on interactions between topographically distinct, yet conformationally …

Allosteric modulation of GPCRs has initiated a new era of basic and translational discovery,
filled with therapeutic promise yet fraught with caveats. Allosteric ligands stabilize unique …